Paraxanthine for Anaerobic Performance

Verdict: Weak, disputed evidence; no clear anaerobic benefit

Current human evidence does not show that paraxanthine on its own improves anaerobic performance such as sprint or peak power output. The two small trials that tested it found no significant effect, so any benefit remains unproven.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

This claim is graded Weak (Tier C) and flagged as disputed because only two very small human RCTs have tested paraxanthine for anaerobic endpoints, and both were null. In a 12-person crossover (PMID 38725238), paraxanthine did not improve Wingate peak or mean power after a 10-km run versus placebo or caffeine. In a 14-person rowing trial (PMID 41918248), paraxanthine alone again showed no significant benefit; only the caffeine-plus-paraxanthine arm was faster (p=0.044, d=0.30), suggesting the signal comes from caffeine synergy rather than paraxanthine itself.

The one strongly positive study (PMID 35215543) was in mice, where 4 weeks of supplementation raised grip strength (+17%) and treadmill endurance (+39%). That is a chronic animal model that does not translate to acute human anaerobic power, and like the human trials it was industry-funded by the patent holder, the basis for the conflict-of-interest flag. There is no systematic review or meta-analysis on this endpoint.

Authoritative bodies offer no support. EU EFSA treats synthetic paraxanthine as an unauthorized novel food with no approved health claims, the UK position is effectively against (it cannot be lawfully sold as a food supplement in Great Britain), and WHO has not addressed it. Mechanistically it acts as an adenosine A1/A2A antagonist like caffeine and appears relatively safe, but its safety is not fully characterized. NIH ODS, Mayo, Cleveland Clinic and Harvard are all silent, which is an absence of evidence, not an endorsement.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
39%
Conflicting evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.446
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Comparative effects of caffeine and paraxanthine on rowing performance and sleep quality: a randomized crossover study
PMID: 41918248 2026 RCT (double-blind) n = 14
Finding: Paraxanthine alone did NOT show clear evidence of performance improvement vs placebo; only the combined caffeine+paraxanthine condition was faster and produced higher mean power (p=0.044, Cohen's d=0.30).
Effect size: PXN alone vs placebo: non-significant (estimate favored PXN but CI crossed null); CAF+PXN vs placebo: d=0.30
View on PubMed
Paraxanthine provides greater improvement in cognitive function than caffeine after performing a 10-km run
PMID: 38725238 2024 RCT (double-blind) n = 12
Finding: No significant differences observed among treatments in post-run anaerobic capacity; paraxanthine did not enhance Wingate power outputs versus placebo or caffeine.
⚠️ Industry-funded Effect size: null (no significant treatment effect on Wingate metrics)
View on PubMed
Paraxanthine Supplementation Increases Muscle Mass, Strength, and Endurance in Mice
PMID: 35215543 2022 Animal Study n = 40
Finding: Grip strength +17% (p<0.001), treadmill performance +39% (p<0.001), soleus mass +41% (p<0.001) vs control — but mouse model, not human anaerobic performance.
🟠 Limited quality ⚠️ Industry-funded Effect size: Reported as % change only; no Cohen's d / SMD
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4b EU EFSA
Cautious
Paraxanthine is manufactured by chemical synthesis. As synthetic paraxanthine was not consumed to a significant degree in the EU before May 15, 1997, it is a novel food according to Regulation (EU) 2015/2283. The identity of synthetic paraxanthine (1,7-dimethyl-3H-purine-2,6-dione) has been analytically verified. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-anaerobic-performance-INT-paraxanthine-001 繁體中文版 →